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Abstract 
Functionalized β-lactams and their derivatives have generated increasing interest in 
medicinal chemistry over the last decades. Because of their pharmacological potential the 
chemistry of fluorinated β-lactams and β-amino acids is considered to be an expanding research 
field. The stereocontrolled synthesis of various fluorine-containing acylic β-lactams has been 
accomplished from some readily available unsaturated bicyclic β-lactam isomers. The synthetic 
strategy was based on ring-opening metathesis of unsaturated bicyclic azetidinones followed 
by cross-metathesis with fluorine-containing olefins. The cross-metathesis transformations, 
performed under various conditions with the aim of studying chemodiscrimination of the olefin 
bonds, resulted in the corresponding functionalized β-lactam derivatives. 
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Introduction 
Azetidin-2-ones or β-lactams have received considerable attention in organic and 
medicinal chemistry. These compounds exhibit a wide range of biological activities. β-Lactam 
antibiotics are amongst the most important antibacterial agents [1, 2]. Other reported activities 
include protease inhibition, cholesterol absorption inhibition, human fatty acid synthase 
inhibition, and antitumor properties [3, 4]. β-Lactams are also valuable synthetic intermediates 
towards heterocycles, β-amino acids, peptides, taxoids, and other compounds [5-8]. 
Because of the high importance of fluorinated biomolecules in drug design, the introduction of 
one or more fluorine atoms into an organic molecule has attracted high interest over the past 
ten years [9-13]. Thanks to the utility of β-lactams, this interest has also been extended to 
fluorine-containing azetidin-2-ones. Such compounds are often synthesized by using a 
fluorinated reactant during heterocyclization [14-19], but late-stage fluorination (fluorine 
introduction after synthesizing the azetidinone skeleton) can also be applied [20]. β-Lactams 
expressed their importance in the synthesis of different fluorinated molecules such as sugar–β-
amino acid conjugates [15], amido esters [18], aminopropanes and heterocycles [17], as well as 
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taxoids and β-amino acids [20]. Relevant bioactivities were reported for fluoro-taxoids [20] and 
some N-aryl-3,3-difluoroazetidin-2-ones [21]. 
One of the most important synthetic developments in the last two decades was the 
emergence of olefin metathesis reactions. This breakthrough was made possible by 
commercially available, highly active Ru-based catalysts tolerating varied functional groups 
(common abbreviations: G1 for Grubbs 1st generation catalysts, G2 for Grubbs 2nd generation 
catalysts, HG1 for Hoveyda–Grubbs 1st generation catalysts, and HG2 for Hoveyda–Grubbs 
2nd generation catalysts) [22, 23]. This powerful, new pathway enabled the synthesis of various 
compounds, which were previously impossible or hard to prepare [24, 25]. 
 
Results and Discussion 
In our earlier recent studies, we have successfully transformed unsaturated bicyclic β-
lactams into functionalized monocyclic azetidinones via a ring-opening metathesis/cross 
metathesis (ROM/CM) sequence [26, 27]. Our current aim was to extend this stereocontrolled 
pathway to the synthesis of fluorine-containing β-lactams utilizing fluorinated olefins in the 
CM step. 
Our first selected substrate was bicyclic lactam (±)-1 derived from 1,5-cyclooctadiene. Its ring 
opening with ethylene was accomplished according to a literature method [26]. 
Functionalization of alkenyl-substituted lactam (±)-2 thus obtained was attempted with three 
different commercially available highly fluorinated alkenes. Cross metathesis reactions in the 
presence of the four commercial catalysts (G1, G2, HG1, HG2) with 2-bromo-3,3,3-trifluoro-
1-propene and 4-bromo-3,3,4,4-tetrafluoro-1-butene failed, but the reaction with allyl 
1,1,2,3,3,3-hexafluoropropyl ether proved to be successful. The best yield of dicoupled product 
(±)-3 was achieved with catalyst HG2 (Scheme 1). 
 
 
 
Scheme 1. Cross-metathesis of lactam (±)-2 with fluorinated alkenes. 
 
Compound (±)-4, our next selected substrate, was obtained by N-Boc protection of lactam (±)-
1. Modification of the reported procedure [28] resulted in an increased product yield of this 
step. ROM of compound (±)-4 was performed analogously to ring opening of (±)-1. Product 
(±)-5 formed in 77% yield was then subjected to CM in the presence of catalyst HG2. Similar 
to cross metathesis of (±)-2, the reaction succeeded with allyl 1,1,2,3,3,3-hexafluoropropyl 
ether to afford compound (±)-6, but failed with 2-bromo-3,3,3-trifluoro-1-propene and 4-
bromo-3,3,4,4-tetrafluoro-1-butene (Scheme 2). 
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Scheme 2. Cross-metathesis of Boc-protected lactam (±)-5 with fluorinated alkenes. 
 
We continued our work with bicyclic lactam (±)-7 (a regioisomer of lactam (±)-1) derived from 
1,3-cyclooctadiene. Its ring opening with ethylene was accomplished according to a literature 
method described earlier [26]. Taking into account the CM reactions on Scheme 1 and Scheme 
2, functionalization of the resulting (±)-8 was attempted only with allyl 1,1,2,3,3,3-
hexafluoropropyl ether. The transformation, carried out in the presence of catalyst HG2, gave 
dicoupled product (±)-9 in a yield of 35% (Scheme 3). 
 
 
Scheme 3. Cross-metathesis of lactam (±)-8 with fluorinated alkene. 
 
Next, bicyclic lactam (±)-10 (N-Boc-protected derivative of (±)-7) was synthesized. Its reaction 
with ethylene was performed analogously to ROM of compounds (±)-1 and (±)-4. Cross 
metathesis of the obtained (±)-11 with allyl 1,1,2,3,3,3-hexafluoropropyl ether produced not 
only dicoupled product (±)-12 but the formation of monocoupled product (±)-13 was also 
observed (Scheme 4). 
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Scheme 4. Cross-metathesis of lactam (±)-11 with fluorinated alkene. 
 
Two factors can contribute to the outcome of this reaction. First of all, chelation of the 
metallacycle intermediate with carbonyl oxygens is known to hinder further reactions by 
stabilizing the metallacycle [29-31]. During metathesis of the vinyl group attached directly to 
the lactam ring of (±)-11, formation of a 6-membered chelate ring with the oxo group of Boc is 
possible (Scheme 5, (±)-T2 (±)-T3). As a result, reactivity of the C=C bond decreases. Another 
plausible factor is steric hindrance of this vinyl group attached to the highly substituted 
azetidinone ring, which slows down its reaction with the Ru-alkylidene catalyst (Scheme 5). 
 
 
Scheme 5. Formation of mono-metathesized product (±)-13 and decoupled product (±)-12. 
 
In continuation, lactam (±)-14 and its N-Boc-protected derivative (±)-19 were subjected to 
ROM according to our previous works [26, 27]. Cross metathesis of allyl 1,1,2,3,3,3-
hexafluoropropyl ether with compounds (±)-15 and (±)-20 provided temperature-dependent 
results (Scheme 6 and Scheme 7). Under reflux in CH2Cl2 both (±)-15 and (±)-20 gave the 
corresponding dicoupled products (±)-16 and (±)-21. At room temperature, in turn, both (±)-15 
and (±)-20 were transformed into 1.5:1 mixtures of two monocoupled products. This outcome 
is similar to our previous results on the chemoselectivity of CM reactions [26, 27]. 
Unfortunately, separation of the product mixtures in both cases was unsuccessful. 
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Scheme 6. Cross-metathesis of lactam (±)-15 with fluorinated alkene. 
 
 
Scheme 7. Cross-metathesis of lactam (±)-20 with fluorinated alkene. 
 
Conclusions 
In the current work access to novel β-lactams, possessing fluorine atoms in their 
substituents, formed under cross-metathesis (CM) reaction conditions has been described. The 
synthetic concept involved the transformation of various diolefinated β-lactams across CM by 
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using fluorine-containing alkene building elements. CM reaction of the dialkenylated β-
lactams, depending on their structure, furnished interesting di- or monocoupled functionalized 
derivatives. Stereochemical factors through chelate ring formation provide plausibly 
explanation for the outcome of the CM reactions. Further investigations in view of the synthesis 
through CM of novel fluorine-functionalized β-lactams are currently being studied in our 
laboratories. 
 
Experimental 
General information 
Chemicals were purchased from Sigma-Aldrich. Solvents were used as received from the 
suppliers. Melting points were determined with a Kofler apparatus. Elemental analyses were 
performed with a Perkin–Elmer CHNS-2400 Ser II elemental analyser. Silica gel 60 F254 was 
purchased from Merck. NMR spectra were acquired at room temperature on a Bruker Avance 
400 spectrometer (1H frequency 400.13 MHz; 19F frequency 376.50 MHz, 13C frequency 100.76 
MHz) or Bruker Avance Neo spectrometer (1H frequency 500.20 MHz; 19F frequency 470.66 
MHz, 13C frequency 125.78 MHz) in CDCl3 or D6-DMSO solution, using the deuterium signal 
of the solvent to lock the field. The 1H and 13C chemical shifts are given relative to TMS and 
those of 19F to CFCl3 (0.00 ppm). 
General Procedure for Ring-Opening Metathesis 
β-Lactam (500 mg) was dissolved in anhydrous CH2Cl2 (100 ml) and Grubbs 1st generation 
catalyst (2 mol%) was added. The mixture was stirred at 20 °C under ethylene for 3 hours 
monitored by TLC. When the reaction was complete, the solution of NaHCO3 (0.3 g) in H2O 
(25 ml) and EtOH (5 ml) was added, and the mixture was stirred at 20 °C for another 2 hours 
with the aim of deactivating the catalyst. Then H2O (30 ml) was added and the mixture was 
extracted with CH2Cl2 (3×40 ml). The organic layer was dried (Na2SO4) and concentrated under 
reduced pressure. The crude material was purified by column chromatography on silica gel (n-
hexane/EtOAc or n-hexane/acetone). 
General Procedure for Cross Metathesis 
β-Lactam (150 mg) was dissolved in anhydrous CH2Cl2 (30 ml) and then Hoveyda-Grubbs 2nd 
generation catalyst (5 mol%) and 3-(1,1,2,3,3,3-hexafluoropropoxy)prop-1-ene (4 equiv.) were 
added. The mixture was stirred at 40 °C under argon atmosphere for 6 hours monitored by TLC. 
When the reaction was complete, the solution of NaHCO3 (0.3 g) in H2O (25 ml) and EtOH (5 
ml) was added, and the mixture was stirred at 20 °C another 2 hours (catalyst deactivation). 
After the addition of H2O (20 ml) the mixture was extracted with CH2Cl2 (3×30 ml). The organic 
layer was dried (Na2SO4) and concentrated under reduced pressure. The crude material was 
purified by column chromatography on silica gel (n-hexane/EtOAc or n-hexane/acetone). 
General Procedure for the Preparation of N-Boc-Protected Lactams 
β-Lactam (200 mg) was dissolved in THF (40 ml) then triethylamine (3 equiv.), di-tert-butyl 
dicarbonate (1.5 equiv.), and 4-dimethylaminopyridine (0.3 equiv.) were added at 0 °C. The 
mixture was stirred for 1 hour, then it was warmed to room temperature with stirring continued 
for 24 hours. When TLC indicated complete reaction, H2O (30 ml) was added, and the mixture 
was extracted with EtOAc (3×20 ml). The organic layer was dried (Na2SO4) and concentrated 
under reduced pressure. The crude material was purified by column chromatography on silica 
gel (n-hexane/EtOAc 10:1). 
 
For characterization and NMR data of the new compounds see Supporting Information. 
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